【摘要】：目的:觀察沙美特羅替卡松聯(lián)合羅紅霉素對(duì)老年支氣管擴(kuò)張患者肺功能和炎癥因子的影響。方法:將82例老年支氣管擴(kuò)張患者隨機(jī)均分為觀察組和對(duì)照組。兩組患者均給予適當(dāng)吸氧、支氣管舒張藥、祛痰藥和止咳藥等常規(guī)治療。在此基礎(chǔ)上,對(duì)照組患者給予羅紅霉素分散片0.15 g,口服,每天2次;觀察組患者在對(duì)照組治療的基礎(chǔ)上給予沙美特羅替卡松粉吸入劑,每天2吸。兩組患者療程均為6個(gè)月。觀察兩組患者治療前后生活質(zhì)量評(píng)分和呼吸困難評(píng)分、肺功能指標(biāo)[1秒用力呼氣容積(FEV1)、FEV1占預(yù)計(jì)值百分比(FEV1%)、FEV1占用力肺活量比值(FEV1/FVC)]、動(dòng)脈血?dú)庵笜?biāo){動(dòng)脈血氧分壓[p(O2)]、動(dòng)脈血二氧化碳分壓[p(CO2)]}、炎性因子[白細(xì)胞介素(IL)-4、IL-6、IL-10、金屬蛋白酶(MMP)-9、超敏C反應(yīng)蛋白(hs-CRP)]及不良反應(yīng)發(fā)生情況。結(jié)果:治療前兩組患者生活質(zhì)量評(píng)分、呼吸困難評(píng)分、肺功能指標(biāo)、動(dòng)脈血?dú)庵笜?biāo)、炎癥因子比較,差異均無統(tǒng)計(jì)學(xué)意義(P0.05)。治療后兩組患者生活質(zhì)量評(píng)分、呼吸困難評(píng)分、p(O2)、IL-4、IL-6、MMP-9、hs-CRP均顯著低于同組治療前,且觀察組低于對(duì)照組;肺功能指標(biāo)、p(CO2)、IL-10均顯著高于同組治療前,且觀察組高于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者治療期間均未見明顯不良反應(yīng)發(fā)生。結(jié)論:沙美特羅替卡松聯(lián)合羅紅霉素可改善老年支氣管擴(kuò)張患者的肺功能,減輕炎癥反應(yīng),安全性較好。
[Abstract]:Aim: to observe the effects of salmeterol and roxithromycin on pulmonary function and inflammatory factors in elderly patients with bronchiectasis. Methods: 82 old patients with bronchiectasis were randomly divided into observation group and control group. Two groups of patients were given appropriate oxygen inhalation, bronchodiastolic drugs, expectorant and cough medicine routine treatment. On this basis, the patients in the control group were given roxithromycin dispersible tablets 0.15 g orally, twice a day, while the patients in the observation group were given salmeterolticasone powder inhalation 2 times a day on the basis of the treatment in the control group. The course of treatment was 6 months. The scores of quality of life and dyspnea before and after treatment were observed in the two groups. Pulmonary function index [forced expiratory volume (FEV1) in one second, FEV1 / predicted percentage (FEV1%), FEV1 occupied vital capacity ratio (FEV1/FVC)], arterial blood gas index {arterial partial pressure of oxygen [p (O2)], arterial partial pressure of carbon dioxide [p (CO2)]}, inflammatory factor [interleukin (IL) -4IL-6 / IL-10, metalloprotein] Enzyme (MMP)-9, hypersensitive C reactive protein (hs-CRP), and adverse reactions. Results: there was no significant difference in quality of life score, dyspnea score, pulmonary function index, arterial blood gas index and inflammatory factor between the two groups before treatment (P0.05). After treatment, the scores of quality of life (QOL), dyspnea score (P (O2) and IL-6 / MMP-9hs-CRP in the two groups were significantly lower than those in the control group and before treatment, and the lung function index (CO2) IL-10 was significantly higher than that in the same group and the control group, and the level of IL-10 in the observation group was higher than that in the control group, and the level of IL-10 in the observation group was significantly higher than that in the control group. The difference was statistically significant (P0.05). No significant adverse reactions occurred during treatment in both groups. Conclusion: salmeterol combined with roxithromycin can improve pulmonary function and reduce inflammation in elderly patients with bronchiectasis.
【作者單位】： 崇州市人民醫(yī)院呼吸內(nèi)科;
【分類號(hào)】：R562.22

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 郭平珍,焦金海,李書玲;支氣管擴(kuò)張黏液栓的影像診斷[J];中國醫(yī)學(xué)影像技術(shù);2000年12期

2 邱志楠,潘俊輝;中西醫(yī)結(jié)合治療支氣管擴(kuò)張合并感染128例臨床觀察[J];新中醫(yī);2001年01期

3 張湘燕 ,李丹 ,宋新靈 ,鄧奇平;高分辨率CT對(duì)支氣管擴(kuò)張的診斷價(jià)值[J];貴州醫(yī)藥;2001年12期

4 徐崇明,李海斌,尹小R，

本文編號(hào)：2203207